AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMUGENE LTD

0.260

+0.0104.00%

Volume:261.77K

Turnover:66.61K

Market Cap:83.59M

PE:-0.82

High:0.260

Open:0.250

Low:0.250

Close:0.250

52wk High:1.496

52wk Low:0.240

Shares:321.52M

Float Shares:254.20M

Volume Ratio:0.72

T/O Rate:0.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.316

EPS(LYR):-0.316

ROE:-84.54%

ROA:-37.27%

PB:1.86

PE(LYR):-0.82

Loading ...

Overview Company News Filings

Concept

Pharmaceutical Companies+1.53%

Capital Flow

Inflow:

Outflow:

News

Dimerix Appoints CFO

MT Newswires Live

FiberPro Secures KRW4.89 Billion Inertial Measurement Unit Supply Contract; Shares Jump 18%

MT Newswires Live

Imugene Ltd-Executive Update

THOMSON REUTERS

Imugene's Phase 1b Study Date Confirmed by FDA to Support Phase 3 Registrational Study, Shares Jump 6%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMU.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","market":"AU","secType":"STK","nameCN":"IMUGENE LTD","latestPrice":0.26,"timestamp":1770682591952,"preClose":0.25,"halted":0,"volume":261767,"delay":0,"changeRate":0.040000000000000036,"nameEN":"IMUGENE LTD","floatShares":254199099,"shares":321515615,"eps":-0.315594,"marketStatus":"Trading","change":0.01,"latestTime":"02-10 11:30:07 AEDT","open":0.25,"high":0.26,"low":0.25,"amount":66614,"amplitude":0.04,"askPrice":0.26,"askSize":45711,"bidPrice":0.255,"bidSize":53627,"shortable":3,"etf":0,"ttmEps":-0.315594,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770699600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.25,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":0.715243,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","floatShares":254199099,"roa":"-37.27%","roe":"-84.54%","lyrEps":-0.315594,"volumeRatio":0.715243,"shares":321515615,"dividePrice":0,"high":0.26,"amplitude":0.04,"preClose":0.25,"low":0.25,"week52Low":0.24,"pbRate":"1.86","psRate":"19.01","week52High":1.496,"institutionHeld":0,"latestPrice":0.26,"committee":0.079688,"eps":-0.315594,"divideRate":0,"volume":261767,"delay":0,"ttmEps":-0.315594,"open":0.25,"prevYearClose":0.365,"prevWeekClose":0.245,"prevMonthClose":0.28,"prevQuarterClose":0.365,"fiveDayClose":0.275,"twentyDayClose":0.34,"sixtyDayClose":0.33},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMU.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-07-02","symbol":"IMU.AU","type":"split","dateTimestamp":1751378400000,"forFactor":34,"toFactor":1,"ratio":34}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMU.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2605114264","title":"Dimerix Appoints CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2605114264","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605114264?lang=en_us&edition=fundamental","pubTime":"2026-01-21 06:24","pubTimestamp":1768947849,"startTime":"0","endTime":"0","summary":"Dimerix (ASX:DXB) appointed Mike Tonroe as chief financial officer, effective Jan. 29, according to a Wednesday filing with the Australian bourse.Tonroe brings over 30 years of experience, having most recently served as the CFO of Imugene (ASX:IMU), the filing added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7508","BK7067","IMU.AU","DXB.AU"],"gpt_icon":0},{"id":"2604165686","title":"FiberPro Secures KRW4.89 Billion Inertial Measurement Unit Supply Contract; Shares Jump 18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604165686","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604165686?lang=en_us&edition=fundamental","pubTime":"2026-01-20 12:02","pubTimestamp":1768881728,"startTime":"0","endTime":"0","summary":"FiberPro (KOSDAQ:368770) secured an inertial measurement unit (IMU) supply contract from Viavi Solutions, according to a Tuesday filing with the Korean Exchange.The deal is valued at 4.89 billion won.Shares of the precise motion measurement solutions provider jumped nearly 18% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0},{"id":"2600055351","title":"Imugene Ltd-Executive Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2600055351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600055351?lang=en_us&edition=fundamental","pubTime":"2026-01-02 12:46","pubTimestamp":1767329217,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nTUECCVBQT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMU.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2589438379","title":"Imugene's Phase 1b Study Date Confirmed by FDA to Support Phase 3 Registrational Study, Shares Jump 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589438379","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589438379?lang=en_us&edition=fundamental","pubTime":"2025-12-08 11:38","pubTimestamp":1765165122,"startTime":"0","endTime":"0","summary":"Imugene  said the US Food and Drug Administration  confirmed data from the current phase 1b study with azer-cel therapy candidate plus IL-2 dosing regimen, including lymphodepletion conditioning, along with the safety profile, supported advancing to phase three registrational study, according to a Monday Australian bourse filing.It received written minutes from the FDA following its recent Type C meeting. This included directional confirmation that its proposed regimen for the pivotal program, which includes augmented lymphodepletion followed by a flat 500 million cell dose of azer-cel with 14 days of subcutaneous low-dose IL-2, is appropriate.The regulator endorsed the firm's dual-end point strategy, with overall response rate and durability being used for accelerated approval, and progression-free survival being used for full approval. It also asked that the control arm include several investigator-choice therapies.The third line and later diffuse large B-cell lymphoma, including pat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IMU.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Pharmaceutical Companies","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":0.015296}]}}